 VICTORIA, British Columbia--BUSINESS WIRE--Aurinia Pharmaceuticals Inc. NASDAQ: AUPH Aurinia or the Company today announced the addition of two novel assets that will expand the Companys rare autoimmune and kidney-related disease pipeline. Over the past year, in anticipation of building out and diversifying our development pipeline, we have brought on additional large and small molecule expertise that uniquely aligns with Aurinias focus on immunology and nephrology, said Peter Greenle 